2
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
629
pembrolizumab
559
Magnetic Resonance Spectroscopy
539
Carboplatin
423
Cyclophosphamide
371
Cisplatin
371
Biopsy
357
Paclitaxel
304
Nivolumab
301
Gemcitabine
299
Radiotherapy
270
Bevacizumab
238
Dexamethasone
207
fludarabine
205
Docetaxel
189
durvalumab
178
atezolizumab
176
Oxaliplatin
172
Fluorouracil
167
venetoclax
164
Rituximab
164
Pemetrexed
162
Radiation
159
Doxorubicin
159
Capecitabine
158
Radiosurgery
147
Etoposide
137
Ipilimumab
134
Leucovorin
133
Lenalidomide
130
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled